Accordingly, the reduced NCX3 expression levels, either by enhancing DREAM activity or by genetic knock-out of the antiporter, increases neuronal vulnerability to intracellular Ca2+ overload and cell death in both in vitro and in vivo models mimicking stroke [10,24]. The gene discussed is KCNIP3; the disease is stroke disorder.